Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 133 of the 135 references it cites were found in a registry or an index.

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

Abstract

Background Conventional meta-analyses have shown inconsistent results for efficacy of second-generation antidepressants. We therefore did a multiple-treatments meta-analysis, which accounts for both direct and indirect comparisons, to assess the effects of 12 new-generation antidepressants on major depression. Methods We systematically reviewed 117 randomised controlled trials (25 928 participants) from 1991 up to Nov 30, 2007, which compared any of the following antidepressants at therapeutic dose range for the acute treatment of unipolar major depression in adults: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine. The main outcomes were the proportion of patients who responded to or dropped out of the allocated treatment. Analysis was done on an intention-to-treat basis. Findings Mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine (odds ratios [OR] 1.39, 1.33, 1.30 and 1.27, respectively), fluoxetine (1.37, 1.32, 1.28, and 1.25, respectively), fluvoxamine (1.41, 1.35, 1.30, and 1.27, respectively), paroxetine (1.35, 1.30, 1.27, and 1.22, respectively), and reboxetine (2.03, 1.95, 1.89, and 1.85, respectively). Reboxetine was significantly less efficacious than all the other antidepressants tested. Escitalopram and sertraline showed the best profile of acceptability, leading to significantly fewer discontinuations than…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)60046-5

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 135 references

Research works printed but not linked: 7

  1. Akkaya, 2003, Comparison of venlafaxine XR and reboxetine in terms of efficacy and safety in major depressive disorder, Yeni Symposium, 41, 170
  2. Gagiano, 1993, A double blind comparison of paroxetine and fluoxetine in patients with major depression, Br J Clin Res, 4, 145
  3. McPartlin, 1998, A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice, Prim Care Psychiatry, 4, 127
  4. Ontiveros, 1997, A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression, Br J Clin Res, 8, 23
  5. Schoemaker, 2002, First, randomized, double-blind comparison of mirtazapine (15–45 mg) and fluvoxamine (50–150 mg) in the treatment of depression, Int J Neuropsychopharmacol, 5, 140
  6. Tylee, 1997, A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general-practice, Prim Care Psychiatry, 3, 51
  7. Yang, 2003, Milnacipran versus sertraline in major depressive disorder: a double-blind randomized comparative study on the treatment effect and beta-adrenergic receptor responsiveness, Korean J Psychopharmacol, 14, 387

Cited by

See all 1,654

Metadata

Authors
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., Tansella, M., & Barbui, C.
Affiliations
  • University of Verona (IT)
  • University of Ioannina (GR)
  • University of Oxford (GB)
  • University of Cambridge (GB)
  • University of Bristol (GB)
  • Nagoya City University (JP)
  • Keio University (JP)
  • Cochrane (GB)
Corresponding author
Cipriani, Andrea
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-02
Volume
373
Issue
9665
Pages
746-758
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2149154629
Cited by
1,654
References
135
Citations by year
2026: 30 · 2025: 37 · 2024: 39 · 2023: 45 · 2022: 51 · 2021: 63 · 2020: 101 · 2019: 78 · 2018: 110 · 2017: 106 · 2016: 120 · 2015: 131 · 2014: 115 · 2013: 144 · 2012: 137
FWCI
115.46
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Bristol Research (University of Bristol) (publishedVersion)
Funders
Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
antidepressants, major depressive disorder, second-generation antidepressants, treatment efficacy, treatment acceptability, treatment discontinuation, escitalopram, sertraline, reboxetine, duloxetine, venlafaxine, mirtazapine, paroxetine, fluoxetine, fluvoxamine, bupropion, milnacipran, citalopram
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(09)60046-5
The paper
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., Tansella, M., & Barbui, C. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(09)60046-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.